Consultation launches on the biggest shake-up of NICE's HealthTech programme to date. More innovative healthcare technologies could soon be adopted by the NHS under reforms proposed today by NICE.

There is a simple discount patient access scheme for vadadustat. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact enquiries@medice ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This ...

Tools to help you put the guidance into practice.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Tools to help you put the guidance into practice.

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the vadadustat being ...

Anhydrous sodium thiosulfate (Pedmarqsi) is available on the NHS. It is a possible treatment for preventing hearing loss caused by cisplatin chemotherapy. It is suitable for babies, children and young ...

The evaluation committee considered evidence submitted by MEDICE, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...